title: The role of cyclosporin in prolonging survival in vascularized bone allografts.
abstract: It is known that experimental vascularized bone allografts are subject to host rejection. To be useful clinically, this rejection response would need to be controlled. Cyclosporin is a potent immunosuppressant whose precise role in vascularized bone allograft transplantation has not been established. Using a proven reliable vascularized knee allograft model in inbred rats, cyclosporin was used postoperatively both continuously and short term (14 days after transplant) at 10 mg/kg per day as recipient treatment. Across a strong histocompatibility barrier, continuous cyclosporin was required for long-term graft survival. Short-term therapy delayed rejection for 4 to 6 weeks. However, across a weak histocompatibility barrier, short-term therapy was as effective as continuous therapy in achieving long-term graft survival. The implication is that a limited course of cyclosporin may be clinically successful in sustaining vascularized bone allograft survival, provided the genetic disparity between graft and host has been minimized by genetic matching techniques.
authors.forename: J P
authors.initials: JP
authors.lastname: Paskert
authors.forename: M J
authors.initials: MJ
authors.lastname: Yaremchuk
authors.forename: M A
authors.initials: MA
authors.lastname: Randolph
authors.forename: A J
authors.initials: AJ
authors.lastname: Weiland
mesh_terms: D000818:Animals; D016025:Bone Transplantation; D001842:Bone and Bones / Q000098:blood supply; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D007717:Knee; D051381:Rats; D011919:Rats, Inbred Strains; D014184:Transplantation, Homologous
chemical_list: D003524:Cyclosporins